CHICAGO, Illinois — Abbott Labs on Wednesday announced it had acquired its second optical company this year, purchasing cataract business Visiogen for $400 million.
The company moved into the optical device market in February when it closed on a deal worth $2.8 billion that acquired Advanced Medical Optics, which made devices for cataract and LASIK surgery, as well as contact lens and eye solutions. Visiogen, meanwhile, has developed an intraocular lens that’s implanted in a patient’s eye after the original is removed due to cataract problems.
Visogen, based in California, received approval earlier this year to distribute its lens, called Synchrony, in Europe. Its currently under consideration by the U.S. Food and Drug Administration for distribution here.
John M. Capek, Abbotts’ executive vice president for medical devices, stated that the acquisition shows the company’s commitment to vision care. “Combining Visiogen’s accommodating lens technology with Abbott’s existing medical optics portfolio expands our ability to offer a diverse set of refractive options to our ophthalmic customers and the patients they serve,” Capek stated in a press release.
The deal should close in the fourth-quarter of 2009 pending regulatory approval.
Innovation, influence and business in America's medical cities.
Comments
Post a comment
[...] Abbott Labs is buying the phama unit of Solvay Chemicals in Belgium for $6.6 billion cash. It’s their third big buy this month. They previously bought Evalve Inc. of Menlo Park, Calif., and LASIK surgery equipment maker Visiogen. [...]
Comment by U.S. medical industry complex spending its market subsidies - SmartPlanet — September 28, 2009 @ 2:45 pm
Post a Comment